AHA

In this second part of a two-part video series, MHE editors spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the cost effectiveness of SGLT2 inhibitors.

Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.

Stephen Greene, MD, of Duke University School of Medicine, explains that Inpefa (sotagliflozin), a recently FDA-approved dual SGLT-1 and SGLT-2 inhibitor, aims to reduce cardiovascular death, heart failure, hospitalizations, or urgent heart failure visits among patients with heart failure, chronic kidney disease, type 2 diabetes, and another cardiovascular risk factor.

Ejection fraction is a key factor in how clinicians diagnose, classify and treat heart failure. But you might not know it if you depended solely on ICD-10 codes.

A post-hoc analysis of the SCORED clinical trial identified early benefit for patients taking Inpefa in both heart failure and major adverse cardiovascular events (MACE) related outcomes

Researchers reported positive results at the AHA meeting today from a small, 48-patient study of lepodisiran, a short interfering RNA therapy designed to reduce lipoprotein(a) levels.

An analysis estimated the clinical and economic impact of Inpefa using inputs from a phase 3 trial of the heart failure drug.

Ten patients have been treated with the CRISPR-based gene therapy, the drug developer's chief scientific officer announced today, and high doses have had the intended effect of lowering LDL cholesterol. One study volunteer died five weeks after the infusion from cardiac arrest, but the company says the death was unrelated to the therapy and no changes were made to the study.

A study that randomized villages in China to an intensive blood pressure-lowering program or usual care showed a 15% decrease in all-cause dementia from the program.

In a phase 2 trial, abelacimab achieved a 99% inhibition of Factor XI and a 67% reduction in major or clinically relevant non-major bleeding events.

Healthcare researchers say it’s critical to get more women, Black and Latino participants in clinical trials. It can be done, but researchers and institutions must make the effort.

Several researchers point out that women face higher stress due to family duties, gender roles and social determinants. They say it’s an area worthy of more attention in research.

A study with a unique trial design and a newer endpoint shows Farxiga can improve cardiometabolic outcomes in a subset of patients.

Positive findings from their placebo-controlled trial show that angioplasty is an evidence-based, first-line treatment for patients with stable angina and that they needn't necessarily be treated first with antianginal medications, say the ORBITA-2 investigators.

Results from the SELECT trial presented at the American Heart Association Scientific Sessions meeting suggest that the GLP-1 inhibitor may have a role in cardiovascular disease protection beyond weight loss and diabetes.